Trial reportThe Journal of pediatrics2026
Antenatal Exposure to Medication for Opioid Use Disorder and Infant Outcomes in the Eat, Sleep, Console for Neonatal Opioid Withdrawal Randomized Controlled Trial.
Trial report in The Journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04057820 (Eating, Sleeping, Consoling for Neonatal Withdrawal), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach
Who cites it
1 citing paper in PubMed.
- Interventions to reduce pharmacologic opioid exposure in neonatal opioid withdrawal syndrome: a systematic review and meta-analysis of randomized studies.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
objectiveTo evaluate associations between care approach (usual care vs Eat, Sleep, Console [ESC]) on infant outcomes, and how these associations were modified by medication (buprenorphine or methadone) for opioid use disorder (MOUD). STUDY
designA post hoc, subgroup analysis was conducted on infants with antenatal exposure to MOUD enrolled in Eat, Sleep, Console for Neonatal Opioid Withdrawal (ESC-NOW), a multicenter, stepped-wedge, cluster-randomized controlled trial.
resultsThere were 949 infants enrolled in the Eat, Sleep, Console for Neonatal Opioid Withdrawal trial and exposed to MOUD (604 buprenorphine, 345 methadone). Infants managed with ESC vs usual care were less likely to receive pharmacologic treatment for NOWS (57.4% vs 18.0%; absolute difference 39.4%; 95% CI: 30.6-48.2; P < .001). Length of hospital stay was 5.4 days shorter (95% CI: 1.9, 8.8; P = .003) in the ESC group. Stratified by MOUD type, infants exposed to methadone managed with ESC had a 9.5 day (95% CI: 4.8-14.2) shorter length of treatment than those managed with usual care (11.1 vs 20.6 days). No significant difference was found between care approaches in length of treatment for buprenorphine-exposed infants (12.3 vs 13.1 days; 95% CI: -4.4 to 6.1).
conclusionsUse of the ESC care approach was associated with a decrease in pharmacologic treatment for NOWS and a shorter hospital stay for infants with antenatal MOUD exposure. Methadone exposure was associated with a shorter length of pharmacologic treatment for infants cared for with ESC when compared with usual care, whereas such an association was not seen for buprenorphine exposed infants.
trial registrationhttps://clinicaltrials.gov/study/NCT04057820.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.